Potential endocrine disruption of ovary synthesis in the Christmas Island red crab Gecarcoidea natalis by the insecticide pyriproxyfen.
The effect of the insecticide, pyriproxyfen on early ovary synthesis was examined in the Gecarcinid land crab, Gecarcoidea natalis. Crabs were fed a mixture of either leaf litter and bait containing 0.5% (wt/wt) pyriproxyfen (experimental groups), or a mixture of leaf litter and a control bait containing no pyriproxyfen (control groups), at simulated baiting doses of 2 kg ha(-1) and 4 kg ha(-1), during the period in which G. natalis synthesises its ovaries. A third group of crabs were fed ad libitum either the bait containing 0.5% Pypriproxyfen or the control bait. Pyriproxyfen affected early ovary development in G. natalis. The ovaries from crabs in the experimental groups at all baiting levels had a higher total nitrogen content and dry mass than the ovaries from crabs in the control groups. Pyriproxyfen affected the histology of the ovaries. Ovaries from animals in the experimental groups were more mature, containing more previtellogenic and early vitellogenic oocytes, of a larger diameter, than the ovaries from crabs in the control groups. Significant amounts of pyriproxyfen accumulated within the midgut gland and ovary, the hypothesised target tissues, while minor amounts of pyriproxyfen was accumulated in the muscle, a hypothesised non target tissue. Pyriproxyfen may have stimulated early ovary development and induced synthesis of yolk protein by mimicking methyl farnesoate and thus causing endocrine disruption. Given this, pyriproxyfen should not be used to control invasive insects in environments where gecarcinid and other land crab species are present.
Linton
Stuart
S
School of Life and Environmental Sciences, Deakin University, Geelong, Victoria, Australia. slinton@deakin.edu.au
Barrow
Lauren
L
Davies
Claire
C
Harman
Laura
L
D000818:Animals; D003386:Brachyura / Q000502:physiology*; D052244:Endocrine Disruptors / Q000494:pharmacology; D005231:Fatty Acids, Unsaturated / Q000819:agonists / Q000378:metabolism; D005260:Female; D010053:Ovary / Q000166:cytology / Q000187:drug effects / Q000254:growth & development*; D011725:Pyridines / Q000494:pharmacology*
D052244:Endocrine Disruptors; D005231:Fatty Acids, Unsaturated; D011725:Pyridines; C032429:methyl farnesoate; C055613:pyriproxyfen